艾媒咨询|2020年第三季度中国中药材行业数据监测季度报告

本报告研究涉及企业/品牌/案例：同仁堂、香雪制药、白云山。

数据显示，2020年第三季度，中药材价格指数迎来上涨周期。艾媒咨询分析师认为，受动物类等少数品种拉动影响，预计2020年10-11月中药材指数会持续走高，但是在12月维稳。据调查，绝大多数商户将会在2021年密切关注行业相关政策、谨慎经营，采取减少压货炒作等经营方式。因而，预计中药材市场在2020年末旺季会有一波行情的走高，但随着旺季结束，明年年初的价格会重新回落，随着疫情的常态化，中药材市场行情预期会呈周期性波动的态势。

Data show that in the third quarter of 2020, Chinese Herbal Medicine Price Index ushered in an upward cycle. iiMedia Research believe that by a small number of animals and other species pull the impact of October 2020-november Chinese herbal medicine index is expected to continue to rise, but stable in December. According to the survey, the vast majority of businesses in the 2021 will pay close attention to industry-related policies, prudent management, to reduce speculation and other business practices. As a result, the Chinese herbal medicine market is expected to see a wave of rising prices in the peak season at the end of 2020. However, as the peak season ends, prices will fall back early next year, and as the epidemic becomes more normal, chinese medicinal materials market is expected to be cyclical fluctuations in the situation.

艾媒咨询|2020Q2中国中药材行业季度数据监测报告

本报告研究涉及企业/品牌/案例：云南白药，天士力。

数据显示，2020年4-5月中药材价格指数小幅下降，行情总体较为震荡。艾媒咨询分析师认为，自第二季度起中药材基本不受新冠肺炎疫情影响，市场秩序趋于稳定，但需求仍然不足，中药材基本以减产居多，减产的信号给予商家部分信心，一旦消费情况好转，中药材价格会重新上涨，因此商家谨慎投资与积极备货双管齐下，导致第二季度中药材大盘指数震荡。

Data show that the price index of Chinese medicinal materials declined slightly from April to May 2020, and the market was generally volatile. iiMedia Research believe that since the second quarter, Chinese herbal medicines have basically not been affected by the new coronary pneumonia epidemic. The market order has stabilized, but demand is still insufficient. Basically, Chinese herbal medicines basically reduce production. The signal of reduced production gives businesses some confidence. Once consumed The situation improves, and the prices of Chinese herbal medicines will rise again. Therefore, merchants' cautious investment and active inventory preparation have taken two measures, leading to the second quarter Chinese herbal medicines market index shock.